Recession Fears Grow as Jobs Report Reveals Slowing Hiring, But These 2 Stocks Stand Tall

The U.S. Labor Market has weakened significantly, sparking concerns of an impending recession. The July 2026 Jobs Report revealed that employers cut 23,000 jobs during the month, a far cry from expectations. While it's impossible to confirm whether a recession is imminent, investors would be wise to prepare for one.

Two robust dividend-paying companies stand out as potential safe-havens: Johnson & Johnson (JNJ) and Abbott Laboratories (ABT). Both companies have demonstrated resilience in the face of adversity and boast long histories of annual payout increases.

Johnson & Johnson has faced headwinds, including biosimilar competition and government-led drug price negotiations, but its underlying business remains strong. The company's lifesaving drugs will continue to be in high demand, especially since insurance companies cover the majority of costs. Additionally, Johnson & Johnson is making significant strides in innovation within its core pharmaceutical segment.

The healthcare giant recently earned approval for Icotyde, a groundbreaking oral peptide treatment for plaque psoriasis, and is developing Milvexian, an investigational anticoagulant that could reduce bleeding risks associated with competing medications. Its medtech business has also improved, with the Ottava robotic-assisted surgery system earning clearance.

Abbott Laboratories, meanwhile, may have finally bottomed out after 18 months of poor performance. While its nutrition and diagnostic businesses still face challenges, its core medical device segment remains strong, driven by growth in diabetes care and structural heart segments.